Drug Profile
Batefenterol/fluticasone furoate
Alternative Names: '081/FF; 961081 + fluticasone furoate; FF/'081; FF/GSK-961081; Fluticasone furoate/batefenterol; Fluticasone furoate/GSK-961081; Fluticasone furoate/TD-5959; GSK-961081/FF; GSK-961081/fluticasone furoate; TD-5959/fluticasone furoateLatest Information Update: 02 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline; Theravance
- Developer GSK
- Class Androstadienes; Biphenyl compounds; Bronchodilators; Carbamates; Carboxylic acids; Glucocorticoids; Piperidines; Quinolines; Small molecules
- Mechanism of Action Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists; Muscarinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease
Most Recent Events
- 29 Sep 2021 Discontinued - Phase-I for Chronic obstructive pulmonary disease (In volunteers) in United Kingdom, Australia (Inhalation) prior to September 2021 (GlaxoSmithKline pipeline, Innoviva pipeline, September 2021)
- 29 Sep 2021 Discontinued - Phase-II for Chronic obstructive pulmonary disease in USA (Inhalation) prior to September 2021 (GlaxoSmithKline pipeline, Innoviva pipeline, September 2021)
- 28 Sep 2021 No development reported - Phase-II for Chronic obstructive pulmonary disease in USA (Inhalation) (GlaxoSmithKline pipeline, Innoviva pipeline, September 2021)